An investigation of proteomic data for application in precision medicine

The majority of cancer drug sensitivity models are built utilizing genomic data measured before drug application to predict the steady state sensitivity of an applied drug. Restricting models to this type of data is limiting and can only explain one small piece of the puzzle. Better characterization of cancer cells can be accomplished through the use of proteomic data as this more directly corresponds to cellular activity. We have implemented models that predict cell viability utilizing protein expression measured post drug application. These models are built utilizing the Random Forest, Elastic Net, Partial Least Square Regression and Support Vector Regression algorithms in addition to stacked models. We have also utilized these same algorithms to predict the average protein inhibition of a cancer drug utilizing cell viability screens as input. Protein expression and cell viability data is taken from the HMS-LINCS database. We have shown that cell viability can be effectively predicted utilizing proteomic data and that we can estimate cancer drug protein inhibition utilizing a small number of cell line screens.

[1]  Ranadip Pal,et al.  Algorithms for Drug Sensitivity Prediction , 2016, Algorithms.

[2]  John M. L. Ebos,et al.  Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth , 2014, PLoS Comput. Biol..

[3]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[4]  B. Shruthi,et al.  Proteomics: A new perspective for cancer , 2016, Advanced biomedical research.

[5]  Ranadip Pal,et al.  Analyzing drug sensitivity prediction based on dose response curve characteristics , 2016, 2016 IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI).

[6]  Ranadip Pal,et al.  IntegratedMRF: random forest‐based framework for integrating prediction from different data types , 2017, Bioinform..

[7]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[8]  N. Sneige,et al.  HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. , 2000, American journal of clinical pathology.

[9]  Ranadip Pal,et al.  Investigation of model stacking for drug sensitivity prediction , 2017, BMC Bioinformatics.

[10]  Hong Yan,et al.  Missing value imputation for gene expression data: computational techniques to recover missing data from available information , 2011, Briefings Bioinform..

[11]  E. Marcotte,et al.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses , 2012, Nature Reviews Genetics.

[12]  Mohammad Fallahi-Sichani,et al.  Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis , 2015 .